Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

591
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
591
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

511
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
511
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

725
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
725
Mechanical Ventilation II: Invasive Ventilation01:23

Mechanical Ventilation II: Invasive Ventilation

967
Ventilators are essential medical equipment used to aid patients with respiratory difficulties. Their primary function is to assist or replace spontaneous breathing by providing mechanical ventilation. There are two general classes of mechanical ventilators: negative-pressure and positive-pressure ventilators.
Negative-Pressure Ventilators
Negative-pressure ventilators create a vacuum around the chest or body to draw air into the lungs, simulating breathing. This method does not require an...
967
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

478
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
478
Mechanical Ventilation III: Noninvasive Ventilation01:23

Mechanical Ventilation III: Noninvasive Ventilation

777
Noninvasive positive-pressure ventilation (NIPPV), continuous positive airway pressure (CPAP), and bilevel positive airway pressure (BiPAP) are essential methods in respiratory care. These ventilation techniques offer unique benefits for patients with various respiratory conditions, providing adequate support without requiring intubation. Let's explore how each method is crucial in improving patient outcomes and enhancing respiratory therapy.
Noninvasive Positive-Pressure Ventilation...
777

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulatory arrest time above 30 min have significantly detrimental effects on the outcomes of type a aortic dissection repair.

Journal of cardiothoracic surgery·2026
Same author

On-Table Extubation following Cardiac Surgery: Clinical Outcomes and Associated Cost Reductions from a Single Academic Medical Center.

Journal of cardiothoracic and vascular anesthesia·2025
Same author

Ventricular Rupture With Pseudoaneurysm Causing Compression Effect on the Right Ventricular Cavity.

JACC. Case reports·2025
Same author

Aortic Dissections in the Elderly: Older Age in Patients With Acute Aortic Syndromes Is Associated With Delayed Time to Surgery.

Cureus·2024
Same author

Patients undergoing emergent surgery for type A intramural hematomas or type A aortic dissections have similar outcomes.

Journal of cardiothoracic surgery·2024
Same author

Discussion to: Do age and functional dependence affect outcomes of simultaneous heart-kidney transplantation?

JTCVS open·2023

Related Experiment Video

Updated: Mar 18, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.2K

Challenges faced in long term ventricular assist device support.

Hirohisa Ikegami1, Paul Kurlansky1, Koji Takeda1

  • 1a Department of Surgery, Division of Cardiothoracic Surgery , Columbia University Medical Center , New York , NY , USA.

Expert Review of Medical Devices
|July 5, 2016
PubMed
Summary
This summary is machine-generated.

Ventricular assist devices (VADs) have revolutionized heart failure treatment, improving survival and quality of life. Ongoing advancements aim to overcome remaining challenges in VAD therapy.

Keywords:
End-stage heart failurecomplicationslong termmechanical cardiac supportoutcomepostoperative managementventricular assist device

More Related Videos

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.5K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K

Related Experiment Videos

Last Updated: Mar 18, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.2K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.5K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Management

Background:

  • Ventricular assist devices (VADs) represent a significant advancement in managing end-stage heart failure.
  • Despite technological improvements over decades, challenges persist in VAD therapy.

Purpose of the Study:

  • To review quality of life, survival rates, and complications in patients with VAD support.
  • To discuss the impact of current challenges and future expectations for VAD technology.

Main Methods:

  • Extensive literature review of studies focusing on VAD support outcomes.
  • Analysis of clinical data regarding quality of life, survival, and complications.

Main Results:

  • Technological advancements in VADs have led to improved survival and enhanced quality of life.
  • A decrease in the incidence of complications associated with VAD support has been observed.

Conclusions:

  • Continued technological evolution is expected to further enhance VAD therapy.
  • Optimal patient selection, timing of implantation, and device choice remain critical in clinical practice.